European Medicines Agency recommends granting a marketing authorization for Imatinib Teva

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Imatinib Teva film-coated tablet 100mg and 400mg and Imatinib Teva capsules 100mg and 400mg intended for the treatment of chronic myeloid leukemia (CML). The applicant for this medicinal product is Teva Pharma B.V. Read more here.